Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

Abstract

Aims: The alpha-glucosidase inhibitor acarbose is believed to reduce plasma glucose by delaying hydrolysis of carbohydrates. Acarbose-induced transfer of carbohydrates to the distal parts of the intestine increases circulating glucagon-like peptide 1 (GLP-1). Using the GLP-1 receptor antagonist exendin(9–39)NH 2 , we investigated the effect of acarbose-induced GLP-1 secretion on postprandial glucose metabolism in patients with type 2 diabetes. Methods: In a double-blinded, placebo-controlled, randomized, crossover study, 15 participants with metformin-treated type 2 diabetes (age: 57–85 years, HbA1c: 40–74 mmol/mol) were subjected to two 14-day treatment periods with acarbose or placebo, respectively, separated by a 6-week wash-out period. At the end of each period, two randomized 4-h liquid mixed meal tests with concomitant infusion of exendin(9–39)NH 2 and saline, respectively, were performed. Results: Compared to placebo, acarbose increased postprandial GLP-1 concentrations and decreased postprandial glucose. We observed no absolute difference in the exendin(9–39)NH 2 -induced increase in postprandial glucose excursions between placebo and acarbose periods, but relatively, postprandial glucose was increased by 119 ± 116% (mean ± s.d. ) during exendin(9–39)NH 2 infusion in the acarbose period vs a 39 ± 27% increase during the placebo period ( P = 0.0163). Conclusions: We confirm that acarbose treatment stimulates postprandial GLP-1 secretion in patients with type 2 diabetes. Using exendin(9–39)NH 2 , we did not see an impact of acarbose-induced GLP-1 secretion on absolute measures of postprandial glucose tolerance, but relatively, the effect of exendin(9–39)NH 2 was most pronounced during acarbose treatment.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-20-1121

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 38

Metadata

Authors
Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K.
Affiliations
University of Copenhagen (DK)
Corresponding author
Knop, Filip K
Venue
European Journal of Endocrinology
Published
2021-03
Volume
184
Issue
3
Pages
383-394
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W3119324073
Cited by
37
References
23
Citations by year
2026: 7 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 6 · 2021: 3
FWCI
4.49
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Steno Diabetes Center Copenhagen (SDCC 3.F CMP)
  • Novo Nordisk Fonden (NNF12OC1015904, NNF18SA0034956)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
acarbose, glucagon-like peptide-1, type 2 diabetes, postprandial blood glucose, alpha-glucosidase inhibitors, exendin-9-39, GLP-1 receptor, glucose tolerance, metformin, mixed meal tolerance test
MeSH terms
Aged, Aged, 80 and over, Blood Glucose, Denmark, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gastric Emptying, Humans, Insulin Resistance, Male, Metformin, Middle Aged, Placebos, Cross-Over Studies, Postprandial Period, Acarbose, Insulin-Secreting Cells, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. https://app.cochat.ai/papers/10.1530/eje-20-1121
The paper
Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021). The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology. https://doi.org/10.1530/eje-20-1121

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.